RECIL 2017: New Response Evaluation Criteria in Lymphoma Clinical Trials

New criteria for evaluating response in lymphoma clinical trials—RECIL 2017—have been developed by an International Working Group with the aim of harmonizing...

Issues in Oncology

On the Variance of Cancer Outcomes by Time and Geography

A recent study by Mokdad and colleagues, reviewed in this issue of The ASCO Post, looks at cancer demographic data for 28 cancers...

Skin Cancer

Neoadjuvant Immunotherapy in High-Risk Melanoma: A New Approach

Melanoma is an immunogenic tumor, as it expresses various melanoma-specific antigens. However, it is both biologically...


More Top Stories

Symptom Management

Ethan M. Basch, MD, on Symptom Control and Quality: The Patient’s Voice

Solid Tumors

First-in-Human Experience With Abemaciclib

The investigational cyclin D–dependent kinase (CDK) 4/6 inhibitor abemaciclib was recently evaluated in several solid tumor types in a phase I multicenter trial.1 Given primarily as a single agent and with continuous dosing, abemaciclib showed encouraging early signals of clinical activity not only ...


Outcomes in Patients With Double-Hit Lymphoma After First Complete Remission

In an analysis reported in the Journal of Clinical Oncology, Landsburg et al found no significant benefit of consolidative autologous stem cell transplantation in patients with double-hit lymphoma after first complete remission. They also found evidence of poorer outcome with front-line R-CHOP...

Bladder Cancer

Toni K. Choueiri, MD, on Urothelial Cancer: Trial Results From Borealis-2

Solid Tumors

CDK4/6 Inhibitors: Where They Are Now and Where They Are Headed in the Future

Geoffrey I. Shapiro, MD, PhD, Director of the Early Drug Development Center at the Dana-Farber Cancer Institute, Boston, explained the current research initiatives involving cyclin D–dependent kinase (CDK) 4/6 inhibitors. Mechanism of Action How do CDK4/6 inhibitors work at the cellular level in...

Skin Cancer

Intermittent Vismodegib Regimens in Basal Cell Cancers

In a phase II trial reported in The Lancet Oncology, Brigitte Dréno, MD, of Nantes University, Nantes, France, and colleagues found that two long-term intermittent vismodegib (Erivedge) dosing regimens provided a similar reduction in the number of clinically significant basal cell carcinomas among...

Revisions to the International Neuroblastoma Response Criteria

A consensus statement from a National Cancer Institute–sponsored clinical trials planning meeting, reported in the Journal of Clinical Oncology by Park et al, presents revisions to the International Neuroblastoma Response Criteria (INRC) for assessing treatment response in patients with...

Issues in Oncology

Gabrielle Rocque, MD, on The Oncology Care Model: Transforming Practices

Solid Tumors

Selected Clinical Trials of CDK4/6 Inhibitors

This Clinical Trials Resource Guide includes a selection of actively recruiting clinical trials of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib in multiple tumor types. All of the studies here and many others are listed on the National...


Are Oncologists Discussing Exercise With Patients?

It is well documented that physical activity benefits patients with cancer, both during and after treatment. Exercise helps patients combat both the physical and psychological impacts of cancer treatment, giving them a sense of well-being, control, stress reduction, and empowerment. However,...

click me